Compare Amgen, Inc. (AMGN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Johnson & Johnson — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Johnson & Johnson trades at $257.77 (market cap $618.61B). The key difference: Johnson & Johnson is far larger — about 3.2× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | JNJ | |
|---|---|---|
Market Cap | $196.12B | $618.61B |
Sector | Health | Health |
52-Week High | $388.16 | $267.24 |
52-Week Low | $271.18 | $155.17 |
Enterprise Value | $241.41B | $651.54B |
Dividend Yield | 2.77% | 2.09% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JNJ trades at $257.77, up 0.31% today, with a bullish technical signal and strong support at $255. The company reported Q1 2026 EPS of $2.70, beating expectations, and maintains robust profitability with a 67.82% gross margin and 21.83% net income margin. Analyst consensus is a Buy with a $268.50 price target, and upcoming Q2 earnings on July 15 are a key catalyst.
JNJ's outlook is positive due to consistent earnings beats and solid financial health, but risks include patent expirations and rising debt. The stock offers a reliable dividend and growth potential, though investors should monitor earnings results and debt levels for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
